Induction of epitope-specific neutralizing antibodies against West Nile virus.
Previous studies have established that an epitope on the lateral ridge of domain III (DIII-lr) of West Nile virus (WNV) envelope (E) protein is recognized by strongly neutralizing type-specific antibodies. In contrast, an epitope against the fusion loop in domain II (DII-fl) is recognized by flavivirus cross-reactive antibodies with less neutralizing potential. Using gain- and loss-of-function E proteins and wild-type and variant WNV reporter virus particles, we evaluated the expression pattern and activity of antibodies against the DIII-lr and DII-fl epitopes in mouse and human serum after WNV infection. In mice, immunoglobulin M (IgM) antibodies to the DIII-lr epitope were detected at low levels at day 6 after infection. However, compared to IgG responses against other epitopes in DI and DII, which were readily detected at day 8, the development of IgG against DIII-lr epitope was delayed and did not appear consistently until day 15. This late time point is notable since almost all death after WNV infection in mice occurs by day 12. Nonetheless, at later time points, DIII-lr antibodies accumulated and comprised a significant fraction of the DIII-specific IgG response. In sera from infected humans, DIII-lr antibodies were detected at low levels and did not correlate with clinical outcome. In contrast, antibodies to the DII-fl were detected in all human serum samples and encompassed a significant percentage of the anti-E protein response. Our experiments suggest that the highly neutralizing DIII-lr IgG antibodies have little significant role in primary infection and that the antibody response of humans may be skewed toward the induction of cross-reactive, less-neutralizing antibodies.
Oliphant
Theodore
T
Departments of Medicine, Molecular Microbiology, and Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
Nybakken
Grant E
GE
Austin
S Kyle
SK
Xu
Qing
Q
Bramson
Jonathan
J
Loeb
Mark
M
Throsby
Mark
M
Fremont
Daved H
DH
Pierson
Theodore C
TC
Diamond
Michael S
MS
D000818:Animals; D000906:Antibodies / Q000737:chemistry*; D003001:Cloning, Molecular; D017931:DNA Primers / Q000737:chemistry; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000737:chemistry*; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry; D007075:Immunoglobulin M / Q000737:chemistry; D051379:Mice; D008810:Mice, Inbred C57BL; D017510:Protein Folding; D020349:Surface Plasmon Resonance; D053060:West Nile Virus Vaccines / Q000737:chemistry; D014902:West Nile virus / Q000737:chemistry / Q000276:immunology*
D000906:Antibodies; D017931:DNA Primers; D000939:Epitopes; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D053060:West Nile Virus Vaccines
Science. 2003 Oct 10;302(5643):248
14551429
Virology. 2006 Nov 10;355(1):44-51
16904151
J Virol. 2003 Dec;77(24):13323-34
14645588
J Exp Med. 2003 Dec 15;198(12):1853-62
14662909
Dev Biol (Basel). 2003;114:221-7
14677692
Nature. 2004 Jan 22;427(6972):313-9
14737159
EMBO J. 2004 Feb 25;23(4):728-38
14963486
Science. 1999 Dec 10;286(5447):2156-9
10591647
Science. 1999 Dec 17;286(5448):2333-7
10600742
J Exp Med. 2000 Jul 17;192(2):271-80
10899913
J Virol. 2001 Apr;75(8):4002-7
11264392
J Virol. 2001 May;75(9):4268-75
11287576
Nat Immunol. 2001 May;2(5):410-4
11323694
N Engl J Med. 2001 Jun 14;344(24):1807-14
11407341
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7449-54
11404475
J Virol. 2001 Aug;75(16):7769-73
11462053
J Immunol. 2001 Nov 1;167(9):5273-7
11673542
Cell. 2002 Mar 8;108(5):717-25
11893341
Nucleic Acids Res. 2002 May 15;30(10):e43
12000848
J Virol. 2002 Dec;76(24):13097-100
12438639
J Virol. 2003 Feb;77(4):2578-86
12551996
J Virol. 2006 Dec;80(23):11467-74
16987985
J Virol. 2006 Dec;80(24):12149-59
17035317
Vaccine. 2007 Jan 5;25(3):414-23
16996661
J Immunol. 2007 Feb 1;178(3):1692-701
17237419
J Immunol. 2007 Mar 1;178(5):2699-705
17312111
Virology. 2007 Mar 15;359(2):336-48
17055550
Cell Host Microbe. 2007 Apr 19;1(2):135-45
18005691
Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6986-91
12759475
J Infect Dis. 2003 Jul 1;188(1):5-12
12825165
Virology. 2003 Sep 15;314(1):190-5
14517072
Structure. 2004 Sep;12(9):1607-18
15341726
Am J Trop Med Hyg. 1987 Mar;36(2):427-34
3826503
Nature. 1991 Dec 5;354(6352):389-92
1956400
Cell. 1991 Dec 20;67(6):1121-9
1760840
Virology. 1994 Jun;201(2):285-93
7514319
J Med Virol. 1997 Jul;52(3):309-15
9210041
J Gen Virol. 1998 Oct;79 ( Pt 10):2375-80
9780042
J Virol. 1999 Jan;73(1):783-6
9847388
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2250-5
10051627
J Virol. 2004 Dec;78(23):12919-28
15542644
J Virol. 2004 Dec;78(24):13975-86
15564505
Nat Med. 2004 Dec;10(12):1366-73
15558055
J Gen Virol. 2005 Feb;86(Pt 2):405-12
15659760
Virology. 2005 May 25;336(1):70-82
15866072
Nat Med. 2005 May;11(5):522-30
15852016
Vaccine. 2005 Jun 10;23(30):3915-24
15917113
J Virol. 2005 Jun;79(12):7466-77
15919902
J Virol. 2005 Jul;79(13):8339-47
15956579
Nature. 2005 Sep 29;437(7059):764-9
16193056
J Virol. 2005 Dec;79(23):14606-13
16282460
Virology. 2006 Mar 1;346(1):53-65
16325883
J Gene Med. 2006 Mar;8(3):265-74
16308885
Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6694-9
16617103
J Exp Med. 2006 May 15;203(5):1371-81
16651386
J Virol. 2006 Jul;80(14):6982-92
16809304
Virology. 2006 Aug 1;351(2):432-43
16712897
Virology. 2006 Sep 15;353(1):35-40
16806383
J Virol. 2006 Oct;80(19):9557-68
16973559
J Infect Dis. 2006 Nov 1;194(9):1300-8
17041857
J Virol. 2003 Dec;77(24):12941-9
14645550